vs
Side-by-side financial comparison of AST SpaceMobile, Inc. (ASTS) and Day One Biopharmaceuticals, Inc. (DAWN). Click either name above to swap in a different company.
AST SpaceMobile, Inc. is the larger business by last-quarter revenue ($54.3M vs $39.8M, roughly 1.4× Day One Biopharmaceuticals, Inc.). Day One Biopharmaceuticals, Inc. runs the higher net margin — -49.6% vs -136.2%, a 86.6% gap on every dollar of revenue. On growth, AST SpaceMobile, Inc. posted the faster year-over-year revenue change (2758.2% vs -57.6%).
AST SpaceMobile, Inc. is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States. The company is building the SpaceMobile satellite constellation, a space-based cellular broadband network designed to connect directly to standard, unmodified smartphones. The network is intended to deliver 4G and 5G broadband coverage globally, particularly in remote and underserved regions.
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
ASTS vs DAWN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $54.3M | $39.8M |
| Net Profit | $-74.0M | $-19.7M |
| Gross Margin | — | — |
| Operating Margin | -175.0% | -60.9% |
| Net Margin | -136.2% | -49.6% |
| Revenue YoY | 2758.2% | -57.6% |
| Net Profit YoY | -106.3% | -153.3% |
| EPS (diluted) | — | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $54.3M | — | ||
| Q3 25 | $14.7M | $39.8M | ||
| Q2 25 | — | $33.9M | ||
| Q1 25 | — | $30.8M | ||
| Q3 24 | — | $93.8M | ||
| Q1 24 | — | $0 | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | $0 |
| Q4 25 | $-74.0M | — | ||
| Q3 25 | $-122.9M | $-19.7M | ||
| Q2 25 | — | $-30.3M | ||
| Q1 25 | — | $-36.0M | ||
| Q3 24 | — | $37.0M | ||
| Q1 24 | — | $-62.4M | ||
| Q4 23 | $-31.9M | — | ||
| Q3 23 | $-20.9M | $-46.1M |
| Q4 25 | -175.0% | — | ||
| Q3 25 | -1109.0% | -60.9% | ||
| Q2 25 | — | -103.1% | ||
| Q1 25 | — | -133.5% | ||
| Q3 24 | — | 31.6% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | -136.2% | — | ||
| Q3 25 | -833.7% | -49.6% | ||
| Q2 25 | — | -89.4% | ||
| Q1 25 | — | -117.0% | ||
| Q3 24 | — | 39.5% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.19 | ||
| Q2 25 | — | $-0.29 | ||
| Q1 25 | — | $-0.35 | ||
| Q3 24 | — | $0.38 | ||
| Q1 24 | — | $-0.72 | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.3B | $451.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.4B | $450.9M |
| Total Assets | $5.0B | $513.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.3B | — | ||
| Q3 25 | $2.4B | $451.6M | ||
| Q2 25 | — | $453.1M | ||
| Q1 25 | — | $473.0M | ||
| Q3 24 | — | $558.4M | ||
| Q1 24 | — | $317.9M | ||
| Q4 23 | $155.3M | — | ||
| Q3 23 | $251.7M | $405.5M |
| Q4 25 | $2.4B | — | ||
| Q3 25 | $1.6B | $450.9M | ||
| Q2 25 | — | $460.8M | ||
| Q1 25 | — | $479.5M | ||
| Q3 24 | — | $555.5M | ||
| Q1 24 | — | $296.8M | ||
| Q4 23 | $213.6M | — | ||
| Q3 23 | $287.2M | $389.6M |
| Q4 25 | $5.0B | — | ||
| Q3 25 | $2.6B | $513.8M | ||
| Q2 25 | — | $519.0M | ||
| Q1 25 | — | $534.4M | ||
| Q3 24 | — | $600.8M | ||
| Q1 24 | — | $326.6M | ||
| Q4 23 | $360.9M | — | ||
| Q3 23 | $402.1M | $414.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $65.0M | $-5.8M |
| Free Cash FlowOCF − Capex | $-330.7M | — |
| FCF MarginFCF / Revenue | -609.0% | — |
| Capex IntensityCapex / Revenue | 728.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-790.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.0M | — | ||
| Q3 25 | $-64.5M | $-5.8M | ||
| Q2 25 | — | $-24.8M | ||
| Q1 25 | — | $-59.0M | ||
| Q3 24 | — | $50.8M | ||
| Q1 24 | — | $-49.7M | ||
| Q4 23 | $-24.9M | — | ||
| Q3 23 | $-36.1M | $-37.1M |
| Q4 25 | $-330.7M | — | ||
| Q3 25 | $-302.9M | — | ||
| Q2 25 | — | $-24.8M | ||
| Q1 25 | — | $-59.3M | ||
| Q3 24 | — | $50.0M | ||
| Q1 24 | — | — | ||
| Q4 23 | $-47.2M | — | ||
| Q3 23 | $-109.5M | $-37.1M |
| Q4 25 | -609.0% | — | ||
| Q3 25 | -2055.0% | — | ||
| Q2 25 | — | -73.2% | ||
| Q1 25 | — | -192.8% | ||
| Q3 24 | — | 53.4% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | 728.7% | — | ||
| Q3 25 | 1617.6% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q3 24 | — | 0.8% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 1.37× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTS
| Products | $44.4M | 82% |
| Other | $7.8M | 14% |
| Sat Co | $2.1M | 4% |
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
